New zebrafish technique quickly finds potential treatments for multiple diseases
Skeletal muscle has proved to be very difficult to grow in patients with muscular dystrophy and other disorders that degrade and weaken muscle. Researchers at Boston Children’s Hospital‘s Stem Cell Program now report boosting muscle mass and reversing disease in a mouse model of Duchenne muscular dystrophy, using a “cocktail” of three compounds identified through a new rapid culture system. Adding the same compounds to stem cells derived from patients’ skin cells, they then successfully grew human muscle cells in a dish.
Senior investigator Leonard Zon, MD, director of the Stem Cell Program at Boston Children’s and an investigator with the Howard Hughes Medical Institute, hopes for clinical trials to begin transplanting these cells into patients with muscle loss in the next several years. In the meantime, the screening technique, described in the journal Cell (published online November 7), can also be applied to multiple disorders beyond muscular dystrophy, he says.
The drug screening technique begins with zebrafish. Zon and colleagues placed tiny zebrafish blastomeres—cells from very early stage embryos—into 384-well culture dishes, adding one test compound to each well. This allowed them to screen 2,400 compounds at once, seeking ones that boosted numbers of muscle progenitor cells in the see-through fish as they developed.
The Zon Lab’s earlier work with zebrafish led to a drug derived from prostaglandin that expands numbers of blood stem cells and is now in a Phase II clinical trial. But this time, researchers genetically modified the fish so that newly created muscle progenitor cells would show up in fluorescent green, and muscle fibers in red. This enabled the team to rapidly quantify muscle cells and fibers produced under different conditions, based on visual readouts—without having to examine each well’s contents through laborious biochemical techniques.
“Automated imagers can take a picture to assay all the 384 wells within a matter of a week, as compared with several months with our earlier technique,” says Zon, who is also a member of Boston Children’s Division of Hematology/Oncology as well as the Harvard Stem Cell Institute (HSCI).
The zebrafish tests revealed six compounds that expanded numbers of skeletal muscle progenitor cells. The Zon Lab collaborated with Amy Wagers, PhD, of HSCI and the Joslin Diabetes Center, and C. Ronald Kahn, MD, of Joslin to conduct experiments in a mouse model of Duchenne muscular dystrophy. “One of our chemicals, forskolin, also increased engraftment of progenitors into the muscles of the mice,” Zon says. “We found you could get more muscle mass just by making more progenitors.”
(Forskolin, though not approved by the FDA, has been used since ancient times to treat a variety of disorders and is sold as a dietary supplement.)
3# Patient-specific cells
Zon, Wagers, Kahn and colleagues next turned to human cells in a dish, working with induced pluripotent stem cells (iPS cells) made from the skin cells of patients with Duchenne muscular dystrophy. “Many muscle diseases could not be adequately modeled in iPS cells in the past,” notes Zon. “No one’s been able to get iPS cells to form skeletal muscle.”
The researchers found that a combination of three small molecules (forskolin, basic fibroblast growth factor and a glycogen synthase kinase-3 GSK-3beta inhibitor) was able to reprogram iPS cells into muscle cells that successfully engrafted in mice.
Zon’s next goal is to transplant these muscle cells from the dish into patients through clinical trials he hopes develop within the next several years. He may begin by trying to increase muscle mass in a specific anatomic location, but for a condition like Duchenne muscular dystrophy, he envisions a series of local injections in different parts of the body.
Zon believes that the combination of rapid zebrafish screening with patient-specific iPS cells will greatly speed up therapeutic development, allowing scientists to quickly vet large numbers of compounds and possible culture conditions. They can then enter a much shorter list of compounds into lengthier testing in human iPS cells that recapitulate the disease in question, as well as live mouse models.
“It’s been very hard to figure out the conditions for making different tissues with iPS cells,” Zon says. “We’ve created a very fast system to find what chemicals you need. Because it’s so fast, we don’t need a hypothesis to do an experiment—you can just do the screen, find the result and see what warrants pursuing.”
The zebrafish system can also quickly spot inhibitors of tissue growth; in fact, it grew out of the lab’s desire to find chemicals that blocked muscle development to treat rhabdomyosarcoma, a tumor that grows in skeletal muscle. The Zon Lab is also using it to find chemicals that can block expansion of melanocytes, potentially halting melanoma.
Go deeper with Bing News on:
- Potential coronavirus treatment granted rare disease statuson March 24, 2020 at 1:06 pm
The pharmaceutical giant that makes a promising coronavirus drug has registered it as a rare disease treatment with U.S. regulators, a status that can potentially be ...
- What is Hantavirus? Deadly disease sparks concern – but it’s no Covid-19on March 24, 2020 at 5:06 am
People are really out here worrying that coronavirus just called for back-up: the deadly strain of Covid-19 has topped 300 000 cases worldwide, with deaths above the 13 000-mark. But recent reports of ...
- Thyroid Eye Disease Market projecting a CAGR of 8.53% during the forecast period, 2020-2026on March 23, 2020 at 9:51 pm
According to BlueWeave Consulting, the global Thyroid Eye Disease market has reached USD 182 Million in 2019 and estimated to reach USD 318 Million in 2026 and anticipated to grow by CAGR of 8.53% ...
- Insights into muscle function enhance our understanding of heart diseaseon March 23, 2020 at 6:58 am
Observing new protein structures helps understanding of underlying molecular mechanisms for muscle function, which is crucial for understanding e.g. heart disease. "Time-resolved X-ray scattering ...
- Acceleron Drops Drug for Rare Muscle Disease After Mixed Phase 2 Dataon March 10, 2020 at 6:31 am
Acceleron (NASDAQ: XLRN) drug ACE-083 was being developed as a treatment for Charcot-Marie-Tooth disease, a hereditary nerve disorder that leads to the progressive loss of muscle function.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Human muscle cells
- Stem cell technique winds back aging in human cellson March 24, 2020 at 8:20 pm
The team removed muscle stem cells from elderly mice, treated them ... Now we’ve found that, by tightly controlling the duration of the exposure to these protein factors, we can promote rejuvenation ...
- Method turns back the clock on old human cellson March 24, 2020 at 12:21 pm
After researchers induced old human cells to express a panel of proteins called Yamanaka factors, they returned to a more youthful and vigorous state, according to a new study. The researchers also ...
- How the coronavirus tricks cells into a full-body invasionon March 24, 2020 at 11:33 am
Unfortunately, that’s exactly what makes the novel coronavirus so dangerous. In the period that an infected person is asymptomatic or mildly ill, they could transmit the virus to dozens of other ...
- Researchers rejuvenate aged human cells with stem cell technologyon March 24, 2020 at 9:45 am
... University School of Medicine have used stem cell technology to force old human cells to rejuvenate, reversing the impact that aging has on cells. The study is the first step toward developing an ...
- Old human cells rejuvenated with stem cell technologyon March 24, 2020 at 8:10 am
Old human cells return to a more youthful and vigorous state after being induced to briefly express a panel of proteins involved in embryonic development, according to a new study by researchers at ...